Which antibody discovery platforms do you offer (phage display, single B cell, hybridoma)?

ProteGenix provides a comprehensive suite of antibody discovery platforms to meet diverse research and therapeutic needs: custom hybridoma development, single B cell screening service, and phage display service. We also offer humanized mouse services and phage display service against human libraries for the generation of fully human antibodies. Additionally, we provide polyclonal antibody services for projects where this approach is most appropriate.

Do you provide access to proprietary antibody libraries or rapid immunization protocols?

Yes. Our hybridoma development platform includes a fast-track protocol capable of delivering results in as little as 45 days. Learn more about our RocketAbs platform We also give you access to our innovative proprietary libraries, designed to maximize the chances of identifying high-quality binders. Explore our phage display libraries to find out more

Can I choose the most appropriate platform depending on my target and objectives?

Absolutely. Our team will work closely with you to identify the platform best suited to your specific target and goals. Every project is reviewed by a dedicated PhD-level expert who provides personalized strategic advice, ensuring the selected approach gives you the best possible chances of success.

How do you handle difficult targets such as membrane proteins or low-immunogenic antigens?

Complex projects are where we truly excel. Our team has extensive hands-on experience with challenging targets, including membrane proteins, low-immunogenic antigens, and other difficult-to-address molecules. We apply tailored strategies and leverage our full technical expertise to tackle these projects with the same commitment to success as any other.

What is the typical timeline from target submission to lead antibody identification?

The timeline depends on the discovery platform and the complexity of your target. Typical timelines include: AI de novo discovery: validated sequences in as little as 2–3 days Phage display: lead binders in approximately 4 weeks Single B-cell discovery: around 6 weeks Hybridoma Fast-Track: approximately 45 days During the initial project review, one of our PhD-level experts will recommend the most appropriate strategy and provide a realistic timeline based on your objectives and target characteristics.

Can discovery campaigns be run in parallel for multiple targets?

Yes, absolutely. We are fully equipped to run simultaneous discovery campaigns across multiple targets, allowing you to accelerate your program without compromise on quality or throughput.

Do you offer recommendations on the best discovery strategy for my program?

Yes. Every project benefits from a dedicated review by one of our PhD-level experts, who will assess your target, objectives, and constraints to recommend the most appropriate discovery strategy. You are never left to navigate these decisions alone.

Do I retain full ownership of discovered antibody sequences?

Yes, full ownership of all discovered antibody sequences is transferred to you. There are no hidden restrictions or royalties.

What contingency strategies are in place if no suitable binders are identified?

We don’t give up easily. Our team is committed to finding the solution you need, and we actively explore alternative strategies before concluding a project. In the rare event that no suitable antibody is identified, we back our work with the strongest guarantees on the market: if we do not deliver your antibody, you do not pay the full service price.

Can alternative discovery routes be rapidly implemented?

Yes. If an initial strategy does not yield the expected results, we can rapidly pivot to alternative discovery routes. Our broad platform portfolio and experienced team mean that we always have additional options to explore on your behalf.

What is antibody discovery?

Antibody discovery is the process of identifying antibody candidates that specifically bind to a target antigen. Depending on your project, this can involve technologies such as phage display, single B-cell screening, hybridoma development, or AI-powered de novo antibody design. The goal is to generate high-quality lead antibodies with the affinity, specificity, and developability required for downstream research or therapeutic development.

What is the difference between antibody discovery and antibody engineering?

Antibody discovery focuses on identifying antibodies that bind your target with the desired specificity and biological activity. Antibody engineering begins after suitable lead antibodies have been identified and involves optimizing properties such as affinity, developability, stability, half-life, immunogenicity, or antibody format for research, diagnostic, or therapeutic applications.

What is lead generation in antibody discovery?

Lead generation is the stage of antibody discovery where multiple antibody candidates are identified, screened, and characterized to select the most promising molecules for further development. These lead antibodies typically demonstrate the desired target binding and functional properties and can then progress into engineering, validation, or preclinical development.

What happens after antibody discovery?

Once lead antibodies have been identified, the next steps depend on your development goals. Projects may progress to antibody engineering, affinity maturation, humanization (when required), developability assessment, recombinant expression, functional characterization, or larger-scale production. Our integrated platform enables a seamless transition from antibody discovery through downstream therapeutic antibody development, allowing you to continue working with a single partner throughout your program. Antibody discovery services Transient expression service Antibody characterization service Antibody engineering services Antibody optimization services Single B-Cell screening Hybridoma development Phage display services Custom recombinant antibody production High throughput antibody production service Epitope mapping service Antibody-drug conjugate services Bispecific antibody production service Custom CAR-T cells development AI-driven humanization AI-driven affinity maturation AI-driven developability improvement

Antibody discovery services

Therapeutic Antibody Discovery Services Delivered in as Little as 2–3 Days

Accelerate therapeutic antibody discovery with integrated screening platforms, guaranteed results, and full IP freedom.

4 discovery platforms: Phage Display, Hybridoma, Single B-Cell, AI de novo
Guaranteed results — or you don’t pay the full service price
Full IP ownership on every sequence, no royalties
Go/No-Go checkpoints with dedicated PhD expert at every stage
Complex target expertise

Discuss Your Discovery Project Book a call

4 Discovery Platforms
- Phage Display
- Hybridoma
- Single B-cell
- AI de novo synthesis
Unique Proprietary technologies
- Multiple phage display libraries
- 45-day immunization technology
- AI platform to assist the discovery process
Complex antigen expertise
- PhD experts guidance at every step
- 95% success rate with challenging targets
- Adapted tools such as nanodiscs
- 25 + years of experience

Why Our Antibody Discovery Services Reduce Project Risk

ProteoGenix is the only CRO offering platform-specific result guarantees across all major antibody discovery technologies, with full IP freedom on every project.

3 Clones

GUARANTEED

Single B-Cell Screening
3 Binders

GUARANTEED

Phage Display Service
100% IP-Free

FULL OWNERSHIP

No royalties. No restrictions.
95% Success

SUCCESS RATE

Complex Targets

4 Discovery Platforms

Compare Our Antibody Discovery Platforms

Each platform is purpose-built for specific targets, timelines and project goals. Our experts guide your choice.

In-Vivo Platforms

Single B-Cell Sorting service

BEST FOR: RARE EPITOPES & HIGH DEVELOPABILITY

Achieve ultra-high-affinity 10⁻¹² M in 6 weeks.

★ 3 Clones Guaranteed ★

See Single B-Cell Service
Custom Hybridoma Development

BEST FOR: RELIABLE MABS, BUDGET-CONSCIOUS PROGRAMS

Use our Fast-Track protocol option to get your antibodies in 45 days.

★ 11 Applications Guaranteed ★

Explore Hybridoma Service

In-Vitro Platforms

Phage Display Services

BEST FOR: TOXIC ANTIGENS, FASTEST WET-LAB TIMELINES

Access the world’s first human cancer and autoimmune libraries.

★ 3 Binders Guaranteed ★

Go to Phage Display Service
AI De Novo Discovery

BEST FOR: RAPID TIMELINE WITHOUT IMMUNIZATION

Get sequences validated by our bio-informatician team in only 2-3 days.

★ No Win, No Fee ★

Talk to our Experts

Compare Our Antibody Discovery Services at a Glance

	Single B-Cell	Hybridoma	Phage Display	AI de novo (New!)
Timeline	6 weeks	45 days (Fast-Track option)	4 weeks	2-3 days
Antibody Humanness	Fully human option	Requires humanization	Fully human option	Fully human by design
Species	Humanized mouse, Mouse, Rat, Rabbit, Guinea Pig, Llama & Alpaca, Camel, Dog, Cat, Swine, Horse	Mouse, Rat, Rabbit, Guinea Pig, Llama & Alpaca, Camel, Dog, Cat, Swine, Horse	Human, Camelid, Dog, Cat, Rabbit	Any (in silico)
Best for	Rare epitope, high developability, precise pairing	Cost-effective mAbs, diagnostic applications	Toxic/low-immunogenic antigens, fastest timelines, VHH	Conserved/tolerogenic epitopes, no immunization possible
Guarantee	3 clones	11 applications diagnostic	3 binders	No win, no fee
IP	Full ownership	Full ownership	Full ownership	Full ownership

Skip 3 weeks of humanization:
Fully Human Discovery Platforms

Our fully human antibody solutions skips the humanization step helping reduce downstream development time and accelerate therapeutic antibody development.

Human Phage display libraries

Access ultra-diverse continuously improved human cancer and autoimmune libraries (~10¹⁰ clones per library)

IP-free Humanized mice

Receive 10 high-affinity antibodies and test them in your own lab. You own every sequence with full IP freedom.

AI de novo Discovery

Our new AI de novo service allows us to generate qualitative sequences in only 2-3 days with a no win no fee guarantee.

Our Antibody Discovery Workflow

Go/No-Go Checkpoints Throughout

Your dedicated PhD expert provides strategic recommendations and clear go/no-go checkpoints at each stage — so you always make data-driven decisions, stay in control of your budget, and never advance a failing project.

Target Assessment

Evaluation of antigen structure, and project objectives by our experts.
Hit Generation

Generation of variants using optimized discovery platforms.
Variant Selection

Identification of promising binders using advanced screening technologies.
Lead Characterization & Identification
(optional)

Identification of the best fits according to client’s specific requirements.
Candidate Optimization
(optional)

Refine promising antibody leads for downstream therapeutic development.
Transient Expression
(optional)

Production of the lead candidates from mg to several grams scale-up.

Discuss Your Discovery Project Book a call

Therapeutic antibody discovery services for complex targets

Antibody Discovery for Complex Targets

Therapeutic antibody discovery services built for challenging antigens

Most CROs offer one or two platforms — and fit your project around their capabilities. We do the opposite.

With 4 complementary discovery platforms and deep expertise in challenging antigens, ProteoGenix designs a strategy around your specific target, timeline, and budget. Your dedicated PhD expert analyzes each project individually and recommends the most adapted approach based on target biology, antigen format, intended application, and development objectives. There is no universally superior platform for a given target class — the right answer depends on your specific constraints.

The table below illustrates how our experts think through platform selection for the most common complex target categories.

Discovery Technologies for Difficult Targets

There is not a single platform that always corresponds to a specific target. At ProteoGenix, our PhD Experts use their deep experience and knowledge to recommend the best strategy for your project according to the target’s biolgogy, the antigen format, the application and the project’s objectives.

Target type	Core challenge	Recommended platforms	Scientific rationale
GPCR	Unstable outside native membrane environment	All 4 platforms applicable	Antigen format is the decisive factor Nanodiscs preserve native conformation but require larger quantities → best suited for phage display Micelles, bicelles, and peptides are more practical for immunization-based approaches (hybridoma, single B-cell)
Toxic antigens	Cannot be safely injected for immunization	Phage Display, AI De Novo	Both platforms bypass immunization entirely Phage display: library screening against the toxic antigen without animal exposure AI de novo: computational design from structural data — no antigen required at all
Highly conserved / low-immunogenic targets	Immune tolerance — weak or absent immune response in standard models	Single B-Cell (rabbit), AI De Novo	Rabbits are phylogenetically more distant from humans than mice or NHPs → stronger immune response against conserved epitopes Rabbit antibodies are known for high specificity and affinity AI de novo can computationally target rare or cryptic epitopes inaccessible to immune-based methods
MHC-peptide complexes	High therapeutic relevance; antibody selectivity is critical	Hybridoma (mouse), Humanized mice, Phage Display, AI de novo	All 4 platforms are technically applicable For therapeutic programs, mouse-based or humanized mouse approaches are generally preferred Rabbit single B-cell is feasible but humanization can introduce developability challenges downstream

Facing challenges with a complex antigen?

Discover our specialized services or contact our team to bring your project to life!

Custom Anti-GPCR Antibodies
Custom Virus-Like Particle Antibodies
Custom MHC-peptide complex antibody

Request a Quote Talk to an Antibody Scientist

Screening results identifying selective anti-pHLA antibody candidates for CAR-T cell therapy in melanoma.

Antibody Discovery Case Study: Selective Anti-pHLA Antibodies

Rapid Discovery of Selective Anti-pHLA Antibodies for CAR-T Cell Therapy in Melanoma

An American pharmaceutical company sought to develop a next-generation CAR-T therapy for melanoma by targeting a disease-specific peptide-HLA (pHLA) complex. The challenge? Achieving perfect selectivity. The antibody needed to recognize the target pHLA—a specific peptide presented by an HLA molecule on tumor cells—while completely avoiding cross-reactivity with the same HLA molecule presenting irrelevant or self-peptides.

4 Specific clones identified
3 Phage display libraries screened
>2x 10¹¹ Different clones screened in total

Read the case report Talk to our Experts

VHH discovery workflow illustrating library screening and selection of lead candidates for translational development.

VHH Discovery Case Study: Rapid Identification of High-Quality VHH Lead Candidates

Accelerating VHH Discovery for Translational Development

“Throughout the project, we greatly benefited from ProteoGenix’s strong scientific and technical expertise, as well as the dedication and responsiveness of our main contact. Their support was instrumental in overcoming key challenges and in accelerating the translational development of our lead candidate.”

_ Dr. Uwe Haberkorn (Head of Department) at Heidelberg University

1.5×10¹⁰ VHH library diversity
192 Clones screened
5 Unique VHH sequences delivered

Read the case report Talk to our Experts

Get the antibody format adapted to your project

Bispecific Antibodies
- Broadest range of bispecific formats of the market
- IP-conscious solutions to avoid patented constructs
Antibody Drug Conjugates
- Any formats, drugs or linkers
- >90% DAR homogeneity
CAR-T cell antibodies
- Full IP ownership
- Powered by our proprietary human cancer phage display library
VHHs
- Proprietary naive VHH phage display library for maximum diversity
- Multiple expression system to adapt cost and time

Proteogenix Trusted Antibody Discovery Company

Why ProteoGenix

Why Research Teams Choose ProteoGenix

A Trusted Antibody Discovery Company with 25+ Years of Expertise

As an experienced antibody discovery company, ProteoGenix supports programs from antigen strategy through lead selection and optimization — with integrated CRO capabilities across discovery, engineering, production, and characterization.

Deep Scientific Experience

Our long track record in antibody and protein science helps design robust discovery plans aligned with real therapeutic goals.

Reliable Execution

Established workflows and experienced teams improve consistency, reproducibility, and confidence in the discovery process.

Long-Term Development Support

We support clients beyond discovery with antibody engineering, production, and characterization services as programs advance. For biotech and pharma teams, working with a company with long-standing technical depth reduces uncertainty and supports faster progress toward therapeutic leads.

Trusted by 9,000+ Researchers Worldwide

TELUM Therapeutics, Spain
Verónica Alcolea, Development Manager

“We are thrilled with the success we’ve achieved through our collaboration with ProteoGenix in developing monoclonal antibodies targeting our protein. The antibodies they produced were not only highly selective but also demonstrated exceptional affinity for our target, significantly advancing our research.
ProteoGenix impressed us with their efficiency and speed throughout the process. Their commitment to providing excellent customer service made our experience even better, as they were always available to address our questions and concerns.
We highly recommend ProteoGenix to anyone in need of high-quality antibody development.”
National Cancer Centre, Singapore
Prof Johnny Ong Chin-Ann, MD, PhD, Group leader

“We have been working together with ProteoGenix since 2020. Using phage display, they helped our team to develop several antibodies with effective blocking effects. We are pleased with their services and look forward to continue working together with them as we advance our research and bring the biologics to the clinical stage.”
University College London, Respiratory Medicine
Richard Beatson, Honorary Associate Professor

“We wouldn’t hesitate to recommend Proteogenix to any lab – especially labs that have a challenging project where a collaboration rather than a simple service agreement is likely to be far more productive.”

Scientific Resources

Proven in the literature

Our antibodies appear in peer-reviewed journals and patents worldwide. Explore the evidence.

Antibody Discovery Services FAQ

ProteGenix provides a comprehensive suite of antibody discovery platforms to meet diverse research and therapeutic needs: custom hybridoma development, single B cell screening service, and phage display service. We also offer humanized mouse services and phage display service against human libraries for the generation of fully human antibodies. Additionally, we provide polyclonal antibody services for projects where this approach is most appropriate.
Yes. Our hybridoma development platform includes a fast-track protocol capable of delivering results in as little as 45 days.

Learn more about our RocketAbs platform

We also give you access to our innovative proprietary libraries, designed to maximize the chances of identifying high-quality binders.

Explore our phage display libraries to find out more
Absolutely. Our team will work closely with you to identify the platform best suited to your specific target and goals. Every project is reviewed by a dedicated PhD-level expert who provides personalized strategic advice, ensuring the selected approach gives you the best possible chances of success.
Complex projects are where we truly excel. Our team has extensive hands-on experience with challenging targets, including membrane proteins, low-immunogenic antigens, and other difficult-to-address molecules. We apply tailored strategies and leverage our full technical expertise to tackle these projects with the same commitment to success as any other.
The timeline depends on the discovery platform and the complexity of your target.

Typical timelines include:
- AI de novo discovery: validated sequences in as little as 2–3 days
- Phage display: lead binders in approximately 4 weeks
- Single B-cell discovery: around 6 weeks
- Hybridoma Fast-Track: approximately 45 days
During the initial project review, one of our PhD-level experts will recommend the most appropriate strategy and provide a realistic timeline based on your objectives and target characteristics.
We don’t give up easily. Our team is committed to finding the solution you need, and we actively explore alternative strategies before concluding a project. In the rare event that no suitable antibody is identified, we back our work with the strongest guarantees on the market: if we do not deliver your antibody, you do not pay the full service price.

Discovery Process FAQ

Antibody discovery is the process of identifying antibody candidates that specifically bind to a target antigen. Depending on your project, this can involve technologies such as phage display, single B-cell screening, hybridoma development, or AI-powered de novo antibody design. The goal is to generate high-quality lead antibodies with the affinity, specificity, and developability required for downstream research or therapeutic development.
Antibody discovery focuses on identifying antibodies that bind your target with the desired specificity and biological activity. Antibody engineering begins after suitable lead antibodies have been identified and involves optimizing properties such as affinity, developability, stability, half-life, immunogenicity, or antibody format for research, diagnostic, or therapeutic applications.
Lead generation is the stage of antibody discovery where multiple antibody candidates are identified, screened, and characterized to select the most promising molecules for further development. These lead antibodies typically demonstrate the desired target binding and functional properties and can then progress into engineering, validation, or preclinical development.

Once lead antibodies have been identified, the next steps depend on your development goals. Projects may progress to antibody engineering, affinity maturation, humanization (when required), developability assessment, recombinant expression, functional characterization, or larger-scale production. Our integrated platform enables a seamless transition from antibody discovery through downstream therapeutic antibody development, allowing you to continue working with a single partner throughout your program.

Antibody discovery services	Transient expression service	Antibody characterization service	Antibody engineering services	Antibody optimization services
Single B-Cell screening Hybridoma development Phage display services	Custom recombinant antibody production High throughput antibody production service	Epitope mapping service	Antibody-drug conjugate services Bispecific antibody production service Custom CAR-T cells development	AI-driven humanization AI-driven affinity maturation AI-driven developability improvement

Start Your Antibody Discovery Project with ProteoGenix

Partner with ProteoGenix for antibody discovery services backed by scientific depth, platform capabilities, and more than 25 years of experience in antibody and biologics development. Our integrated CRO model supports biotech and pharma teams from early target analysis through lead optimization and beyond.

Request a Quote Talk to an Antibody Expert

Antibody discovery services

Therapeutic Antibody Discovery Services Delivered in as Little as 2–3 Days

4 Discovery Platforms

Unique Proprietary technologies

Complex antigen expertise

Why Our Antibody Discovery Services Reduce Project Risk

3 Clones

3 Binders

100% IP-Free

95% Success

Compare Our Antibody Discovery Platforms

In-Vivo Platforms

Single B-Cell Sorting service

Custom Hybridoma Development

In-Vitro Platforms

Phage Display Services

AI De Novo Discovery

Compare Our Antibody Discovery Services at a Glance

Skip 3 weeks of humanization: Fully Human Discovery Platforms

Our Antibody Discovery Workflow

Go/No-Go Checkpoints Throughout

Target Assessment

Hit Generation

Variant Selection

Lead Characterization & Identification (optional)

Candidate Optimization (optional)

Transient Expression (optional)

Antibody Discovery for Complex Targets

Therapeutic antibody discovery services built for challenging antigens

Discovery Technologies for Difficult Targets

Antibody Discovery Case Study: Selective Anti-pHLA Antibodies

Rapid Discovery of Selective Anti-pHLA Antibodies for CAR-T Cell Therapy in Melanoma

VHH Discovery Case Study: Rapid Identification of High-Quality VHH Lead Candidates

Accelerating VHH Discovery for Translational Development

Get the antibody format adapted to your project

Bispecific Antibodies

Antibody Drug Conjugates

CAR-T cell antibodies

VHHs

Why Research Teams Choose ProteoGenix

A Trusted Antibody Discovery Company with 25+ Years of Expertise

Trusted by 9,000+ Researchers Worldwide

TELUM Therapeutics, Spain Verónica Alcolea, Development Manager

National Cancer Centre, Singapore Prof Johnny Ong Chin-Ann, MD, PhD, Group leader

University College London, Respiratory Medicine Richard Beatson, Honorary Associate Professor